MedTrace Logo

Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies

NCT07408362 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-13

No results posted yet for this study

Summary

The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy/thoracic radiotherapy). The main questions it aims to answer are:

* Can advanced echocardiography (including strain and myocardial work), ECG, and ergospirometry effectively diagnose earlier subclinical cardiac impairment in this population?
* What is the prevalence of cardiovascular risk factors (including physical activity levels and biological markers like proBNP/troponins)
* Can new genetic or biological markers be identified to help optimizing the detection of CTRCT?

At time of follow-up, if they agree, participants will:

* Complete validated questionnaires regarding quality of life, physical activity, and sedentary behavior.
* Undergo a cardiopulmonary exercise test (ergospirometry) for those aged over 8 years.
* Wear an accelerometer (ActiGraph GT3X) for 7 consecutive days to monitor physical activity.
* Provide an additional blood sample during routine follow-up for the creation of a biobank dedicated to analyzing markers of senescence, fibrosis, apoptosis, and genetic polymorphisms.

Conditions

  • Cancer Therapy-related Cardiovascular Toxicity
  • Childhood Cancer
  • Chemotherapeutic Toxicity
  • Radiotherapy Side Effect
  • Cardiovascular Complication

Interventions

DIAGNOSTIC_TEST

Ergospirometry

Completion of validated, age-appropriate quality of life scales and physical activity assessment forms. Patients over 8 years of age will perform a standardized cardiopulmonary exercise test (CPET / ergospirometry) on a treadmill. Seven-day continuous monitoring using a wearable accelerometer. Collection of a 10 mL blood sample (one EDTA tube and one serum-clotting tube), to be centrifuged and stored at -80°C in the CHU de Liège "BHUL" biobank.

Sponsors & Collaborators

  • Centre Hospitalier Régional de la Citadelle

    collaborator OTHER

  • Centre Hospitalier Universitaire de Liege

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2028-12-31
Completion
2033-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07408362 on ClinicalTrials.gov